While it doesn't garner as many column inches as other industries - probably because it still seems like sci-fi to most people - the nanotechnology industry continues to expand out of the lab and into practical applications. Nanotechnology, the creation and use of devices that are between one and 100 nanometers wide (a nanometer is a billionth of a meter), is today worth an estimated $24 billion ...
Go here to read the rest:
SKOKIE, IL--(Marketwire -04/23/12)- NanoProfessor, a division of NanoInk, Inc. focused on nanotechnology education, announced today that in conjunction with the City Colleges of Chicago, two City Colleges of Chicago students have been selected to participate in the NanoProfessor Internship Program.
Bridget Basan, of Chicago and a student at Wilbur Wright College, and Paulina Szadkowska-Kociszewski, of Chicago and a student at Harry S. Truman College, are participating in a specialized, eight-week training course built around the NanoProfessor Nanoscience Education Program's curriculum and hands-on lab experiments. Once successfully completed, the students will be provided a paid summer internship in which they will assist the NanoProfessor scientific team in developing new, cutting-edge labs for the NanoProfessor Program focused on top-down and bottom-up nanolithography, polymer deposition, and the printing of flexible electronics using NanoInk's proprietary Dip Pen Nanolithography (DPN).
"The selection of Bridget and Paulina as the first students in the NanoProfessor Internship Program marks the first step in our partnership with City Colleges of Chicago to prepare students for careers in the growing field of nanotechnology," said Dean Hart, Chief Commercial Officer at NanoInk. "They will be working side-by-side with our talented team of scientists while gaining valuable hands-on experience using cutting-edge technology such as NanoInk's NLP 2000, which is the first and only desktop nanofabrication system allowing users to quickly and easily build custom-engineered nanoscale structures with a wide variety of materials from metal nanoparticles to biomolecules using NanoInk's proprietary DPN."
"At City Colleges, we focus on providing our students with the training and real-world experiences needed to graduate with credentials of economic value," said Mike Davis, Associate Vice Chancellor of Science Technology Engineering and Math at City Colleges of Chicago. "Experiences like this internship are invaluable to Bridget and Paulina. It will help them find a job after graduation, add to their resume, build their professional network, and let them see science come alive in the professional world."
"I am very happy to be selected for this unique opportunity with the NanoProfessor Program, which will provide me with useful experience as I continue my education and prepare for what I think will be an exciting career in nanotechnology," said Paulina Szadkowska-Kociszewski.
Bridget Basan added, "I am really looking forward to helping the NanoProfessor team develop new labs for the program, especially those focused on working with polymers and flexible electronics given the importance these can have in preparing me and future students for nanotechnology jobs."
The joint program being conducted with the NanoProfessor Nanoscience Education Program and the City Colleges of Chicago builds off of the recently announced Colleges to Careers program, which is a partnership between City Colleges of Chicago and industry leaders to fill the skills gap and ensure residents can win the jobs of today and tomorrow.
About the NanoProfessor Nanoscience Education Program The NanoProfessor Nanoscience Education Program aims to advance undergraduate nanotechnology education and address the growing need for a skilled, nano-savvy workforce. The NanoProfessor Program, including instruments, an expert-driven curriculum, and student/teacher support materials, is available for high schools, community colleges, technical institutes, and universities worldwide. More information is available at http://www.NanoProfessor.net or (847)679-NANO (6266). You can also like NanoProfessor on Facebook at http://www.facebook.com/NanoProfessor1 and follow on Twitter at http://www.twitter.com/nanoprofessor1.
About the City Colleges of ChicagoThe City Colleges of Chicago (CCC) is the largest community college system in Illinois and one of the largest in the nation, with 5,800 faculty and staff serving 120,000 students annually at seven colleges and seven satellite sites city-wide. The City Colleges of Chicago is in the midst of a Reinvention, a collaborative effort to review and revise CCC programs and practices to ensure students leave CCC college-ready, career-ready, and prepared to pursue their life's goals. The City Colleges of Chicago includes seven colleges: Richard J. Daley College, Kennedy-King College, Malcolm X College, Olive-Harvey College, Harry S. Truman College, Harold Washington College, and Wilbur Wright College. The system also oversees the Washburne Culinary Institute, the French Pastry School, two restaurants, five Child Development Centers, the Center for Distance Learning, the Workforce Institute, the public broadcast station WYCC-TV Channel 20, and radio station WKKC-FM 89.3. For more information about City Colleges of Chicago, call (773)COLLEGE or visit http://www.ccc.edu.
NanoInk, NanoProfessor, Dip Pen Nanolithography, DPN, and the NanoProfessor logo are trademarks or registered trademarks of NanoInk, Inc.
Continued here:
The U.S. Food & Drug Administration (FDA) is seeking additional studies into nanotechnology over the unknown side effects on the human body from these very tiny particles.
U.S. regulators just advised food and cosmetic companies to expand their nanotechnology studies. Nanotechnology is, explained Reuters, the design and manufacture of materials that are one-billionth of one meter, which is smaller than what is viewable with a regular light microscope.
Used in hundreds of products, nanotechnology is already found in stain-resistant clothing, cosmetics, and food additives, noted Reuters; however, its human health effects are not clearly understood.
Consider, for instance, that nanoparticles might penetrate skin or move through and between the bodys organs. Scientists are not clear on the effect this activity could have on the body, said Reuters. Because of this, the FDA just issued two draft guidelines that urge for additional research, saying the agency is in early stages of its nanotech review and is looking for companies to take responsibility for product safety, said Reuters.
Understanding nanotechnology remains a top FDA priority, said FDA Commissioner Margaret Hamburg. FDA is strengthening the scientific tools and methods for evaluating food products, cosmetics, drugs, and medical devices, Hamburg added. In the meantime, the FDA has advised companies that the nanotechnology used in food additives or food packaging should be cleared with the agency and should include data indicating that the changes are safe. The consequences (to consumers and to the food industry) of broadly distributing a food substance that is later recognized to present a safety concern have the potential to be significant, said the guide, wrote Reuters.
Prevailing regulations mandate U.S. companies that manufacture food additives and ingredients to prove those ingredients are generally recognized as safe, said Reuters. Because nanotechnology does not automatically fall into this category, the FDA said that companies must provide additional safety data in order to receive approval.
Cosmetic makers must also conduct additional product testing, said Reuters. This means, for example, that more testing would be required on the nanotechnology used to create smoother moisturizers or lipsticks.
We previously wrote about nanotubes, which are feared to pose similar health risks as asbestos. Discovered in 1991, nanotubes are basically rolled-up carbon sheets of tiny, super-strong carbon fibers used to produce materials much lighter and stronger than steel. Nanotubes are found in a variety of common products, such as tennis rackets.
Scientists have long wondered whether needle-shaped Nanotubes might cause similar diseases to those caused by needle-shaped asbestos fibers, such as lung cancer; mesothelioma a cancer of the lining of the chest and abdominal cavity; and asbestosis, in which lungs become scarred with fibrous tissue.
Researchers previously reporting in the journal Nature Nanotechnology conducted testing on the technology and suggested that, in time, the lesions caused by long nanotubes would develop into mesothelioma. Laboratory and nanotube manufacturer workers were believed to be in the most serious danger. Concern was also expressed that nanotubes embedded in a golf club or bicycle frames, which might not be immediately released, could be released later, in much the same way as asbestos in concrete or automobile brake pads was inhaled by construction workers or mechanics.
See more here:
NEW YORK, April 24, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Nanotechnology Industry
The global outlook series on Nanotechnology provides a collection of statistical anecdotes, market briefs, and concise summaries of research findings. The report offers a bird's eye view of this new, promising, and pulsating, potential laden industry. The report provides a rudimentary insight into the concept of nanotechnology, providing selective insights into major technology trends, and its impact on commercial applications in key end-use industries. Also included is a compilation of recent mergers, acquisitions, and strategic corporate developments. Annotated with market data-rich tables enumerating key research findings, the global and regional level of discussion culminates to provide a macro-level perception of the industry in its totality. Key regional markets briefly researched and abstracted include the US, Canada, Japan, Europe, France, Germany, Russia, UK, Asia, China, and Australia among few others. Also included is an indexed, easy-to-refer, fact-finder directory listing the addresses, and contact details of 758 companies worldwide.
1. OVERVIEW 1
Nanotechnology - The Builder's Final Frontier 1
The Coming of Nano-Age 1
Expect the Unexpected 1
A Conceptual Definition 2
What is Nanotechnology? 2
See the original post:
ScienceDaily (Apr. 23, 2012) A team of scientists from Johns Hopkins and elsewhere have developed nano-devices that successfully cross the brain-blood barrier and deliver a drug that tames brain-damaging inflammation in rabbits with cerebral palsy.
A report on the experiments, conducted at Wayne State University in collaboration with the Perinatology Research Branch of the National Institute of Child Health and Human Development, before the lead and senior investigators moved to Johns Hopkins, is published in the April 18 issue of Science Translational Medicine.
For the study, researchers used tiny, humanmade molecules laced with N-acetyl-L-cysteine (NAC), an anti-inflammatory drug used as antidote in acetaminophen poisoning. The researchers precision-targeted brain cells gone awry to halt brain injury. In doing so they improved the animals' neurologic function and motor skills.
The new approach holds therapeutic potential for a wide variety of neurologic disorders in humans that stem from neuro-inflammation, including Alzheimer's disease, stroke, autism and multiple sclerosis, the investigators say.
The scientists caution that the findings are a long way from human application, but that the simplicity and versatility of the drug-delivery system make it an ideal candidate for translation into clinical use.
"In crossing the blood-brain barrier and targeting the cells responsible for inflammation and brain injury, we believe we may have opened the door to new therapies for a wide-variety of neurologic disorders that stem from an inflammatory response gone haywire," says lead investigator Sujatha Kannan, M.D., now a pediatric critical-care specialist at Johns Hopkins Children's Center.
Cerebral palsy (CP), estimated to occur in three out of 1,000 newborns, is a lifelong, often devastating disorder caused by infection or reduced oxygen to the brain before, during or immediately after birth. Current therapies focus on assuaging symptoms and improving quality of life, but can neither reduce nor reverse neurologic damage and loss of motor function.
Neuro-inflammatory damage occurs when two types of brain cells called microglia and astrocytes -- normally deployed to protect the brain during infection and inflammation -- actually damage it by going into overdrive and destroying healthy brain cells along with damaged ones.
Directly treating cells in the brain has long proven difficult because of the biological and physiological systems that have evolved to protect the brain from blood-borne infections. The quest to deliver the drug to the brain also involved developing a technique to get past the brain-blood barrier, spare healthy brain cells and deliver the anti-inflammatory drug exclusively inside the rogue cells.
To do all this, the scientists used a globular, tree-like synthetic molecule, known as a dendrimer. Its size -- 2,000 times smaller than a red blood cell -- renders it fit for travel across the blood-brain barrier. Moreover, the dendrimer's tree-like structure allowed scientists to attach to it molecules of an anti-inflammatory NAC. The researchers tagged the drug-laced dendrimers with fluorescent tracers to monitor their journey to the brain and injected them into rabbits with cerebral palsy six hours after birth. Another group of newborn rabbits received an injection of NAC only.
Go here to see the original:
Public release date: 23-Apr-2012 [ | E-mail | Share ]
Contact: Ekaterina Pesheva epeshev1@jhmi.edu 410-502-9433 Johns Hopkins Medical Institutions
A team of scientists from Johns Hopkins and elsewhere have developed nano-devices that successfully cross the brain-blood barrier and deliver a drug that tames brain-damaging inflammation in rabbits with cerebral palsy.
A report on the experiments, conducted at Wayne State University in collaboration with the Perinatology Research Branch of the National Institute of Child Health and Human Development, before the lead and senior investigators moved to Johns Hopkins, is published in the April 18 issue of Science Translational Medicine.
For the study, researchers used tiny, manmade molecules laced with N-acetyl-L-cysteine (NAC), an anti-inflammatory drug used as antidote in acetaminophen poisoning. The researchers precision-targeted brain cells gone awry to halt brain injury. In doing so they improved the animals' neurologic function and motor skills.
The new approach holds therapeutic potential for a wide variety of neurologic disorders in humans that stem from neuro-inflammation, including Alzheimer's disease, stroke, autism and multiple sclerosis, the investigators say.
The scientists caution that the findings are a long way from human application, but that the simplicity and versatility of the drug-delivery system make it an ideal candidate for translation into clinical use.
"In crossing the blood-brain barrier and targeting the cells responsible for inflammation and brain injury, we believe we may have opened the door to new therapies for a wide-variety of neurologic disorders that stem from an inflammatory response gone haywire," says lead investigator Sujatha Kannan, M.D., now a pediatric critical-care specialist at Johns Hopkins Children's Center.
Cerebral palsy (CP), estimated to occur in three out of 1,000 newborns, is a lifelong, often devastating disorder caused by infection or reduced oxygen to the brain before, during or immediately after birth. Current therapies focus on assuaging symptoms and improving quality of life, but can neither reduce nor reverse neurologic damage and loss of motor function.
Neuro-inflammatory damage occurs when two types of brain cells called microglia and astrocytes normally deployed to protect the brain during infection and inflammation actually damage it by going into overdrive and destroying healthy brain cells along with damaged ones.
See the article here:
Nano-devices that cross blood-brain barrier open door to treatment of cerebral palsy
Wichita State Universitys Center for Innovation and Enterprise Engagement, based out of the School of Engineering, has awarded grants to help develop four high-tech projects.
The grants range from $20,000 to $50,000 and were made after recipients were picked by the centers board of directors after a competition. They were chosen for their unique ideas, potential for commercialization and likely impact on the regions economy. Some of the federal grant money will fund graduate school engineering scholarships.
The award money comes from a $2 million federal grant to promote innovation that WSU won last year. In January, the center awarded grants to Nitride Solutions, JR Custom Metal Products, TSI Technologies, Kansas State University student Isaac Spear and WSU professor Mike McCoy.
The most recent grants went to:
Fairmount Technologies, to develop a study of stretch roll forming processes using experiments and finite element analysis.
Mid-Continent Composites, for accelerated fabrication of a full-scale prototype of a unique Light Sport Aircraft.
Ocianna International, for development and expansion of mooring/anchoring technologies for maritime applications in off-shore wind and wave generators, oil and natural gas exploration/production facilities, and universal water-based off-shore construction.
The center also awarded a grant to WSU faculty member Ramazan Asmatulu, for development of nano-composite spheres for application of self-healing composite materials for wind turbine blades.
Follow this link:
Public release date: 24-Apr-2012 [ | E-mail | Share ]
Contact: Richard Merritt richard.merritt@duke.edu 919-660-8414 Duke University
DURHAM, N.C. -- Microscopic particles are being coaxed by Duke University engineers to assemble themselves into larger crystalline structures by the use of varying concentrations of microscopic particles and magnetic fields.
These nano-scale crystal structures, which until now have been difficult and time-consuming to produce using current technologies, could be used as basic components for advanced optics, data storage and bioengineering, said the research team.
"Not only did we develop the theoretical underpinning for this new technique, but we demonstrated in the lab that we could create more than 20 different programmed structures," said Benjamin Yellen, assistant professor of mechanical engineering and materials science at Duke's Pratt School of Engineering and lead member of the research team. The results of the Duke experiments were published online in the journal Nature Communications.
"Despite the promise of creating new classes of man-made structures, current methods for creating these tiny structures in a reliable and cost-effective way remains a daunting challenge," Yellen said. "This new approach could open pathways for fabricating complex materials that cannot be produced by current techniques."
The research was supported by the Research Triangle Materials Research Science and Engineering Center, which is funded by the National Science Foundation.
The traditional method for creating man-made crystals is described as "top-down" by Yellen, which means they are fashioned by lithography or molding techniques, and can't be easily created in three dimensions.
"Our approach is much more 'bottom up,' in that we're starting at the level of a model 'atom' and working our way up," Yellen said.
By manipulating the magnetization within a liquid solution, the Duke researchers coaxed magnetic and non-magnetic particles to form intricate nano-structures, such as chains, rings and lattices.
View post:
HIV-1, the AIDS virus, spreads mainly via unprotected sexual contacts in China including Hong Kong. Over 90% of recently identified infections is due to sexual transmission in Hong Kong. After the HIV-1 enters human body, it establishes persistent and latent infections quickly which makes current antiviral therapy fail to cure the patients. Since an effective AIDS vaccine remains elusive, it is important to develop a highly effective drug to prevent HIV-1 sexual transmission. With the support of National 11th Five-Year Research Project and HKU Developmental Fund, AIDS Institute of The University of Hong Kong Li Ka Shing Faculty of Medicine discovers a novel molecular mechanism of a potent anti-HIV CCR5 antagonist TD-0680 in close collaboration with Shanghai Targetdrug Co. Ltd, Nanjing University and City University of Hong Kong. This drug candidate is potent against a clinical CCR5 antagonist-resistant HIV-1, and is an attractive candidate drug for preventing HIV-1 sexual transmission once developed as a topical microbicide gel. The research article has recently been published in The Journal of Biological Chemistry, a top journal in the area of drug mechanism study.
Research Background and Methodology
HIV-1 enters human cells by binding with the human receptor CD4 and a co-receptor CCR5. Since sexually transmitted HIV-1 strains adhere mainly to CCR5 (i.e. CCR5-tropic), CCR5 antagonist can effectively block the interaction between the virus and CCR5, thus prevent the virus from entering human cells, and thereby, avoid persistent and latent infections.
To date, Maraviroc is the only CCR5 antagonist approved by the Food and Drug Administration in the United States for clinical treatment. After almost 5 years of clinical application of this drug, Maraviroc-resistant HIV-1 has already emerged. It is, therefore, necessary to discover novel CCR5 antagonists and strategies to overcome the resistant virus. Using viral infection, gene mutagenesis, drug combination assay, molecular modeling and docking, inhibition of monoclonal antibody and other methods, the collaborative team discovered a novel molecular mechanism of a potent anti-HIV CCR5 antagonist (TD-0680).
Research Results
The findings indicated that the small molecule TD-0680 is currently the most potent anti-HIV CCR5 antagonist. Its antiviral activity is several to over ten-fold higher than Maraviroc. TD-0680 displays broad reactivity against both human and monkey AIDS viruses. Besides inhibiting cell-free viruses, it also blocks cell-mediated viral transmissions with similar potency, which is over one thousand-fold better than a reverse transcriptase inhibitor Tenofovir (TDF). A vaginal microbicide gel containing TDF was shown to reduce HIV-1 infection rates by 39% recently. In addition, TD-0680 is potent against a known Maraviroc-resistant HIV-1.
The newly discovered molecular mechanism of TD-0680 involves the blockade of two functional regions of CCR5, which forms a tougher barrier as if a door with double locks to prevent virus from entering the target cell. The study is the first discovery of a CCR5 antagonist which uses such a unique mechanism.
Research Implications
The principal investigator of the study, Dr. Zhiwei CHEN, Director of AIDS Institute of The University of Hong Kong Li Ka Shing Faculty of Medicine emphasises "Unprotected sexual contact is the major risk factor for the spread of HIV/AIDS among general populations in China. In 2011, it has led to a record high of HIV infections in Hong Kong. It is urgently needed to discover a biomedical means to prevent HIV sexual transmission, which is important for AIDS prevention in China and in the world." He adds, "The ideal solution is to develop an effective vaccine. Since such a vaccine remains elusive, we must explore other strategies such as topical microbicide. The discovery of the mechanism and potency of TD-0680 is encouraging. It may not only be developed as a therapy for treating AIDS patients, but may also be used to prevent HIV sexual transmission after being formulated into vaginal or rectal microbicide gels, therefore giving people, especially women, an alternative method to protect themselves from the virus, in addition to condoms."
SOURCE: The University of Hong Kong
See the article here:
HKU Collaborative Research Discovers A Novel Molecular Mechanism Of A New Anti-HIV-1 Drug Candidate
Cutting down on repeated nuclear and molecular imaging scans due to poor quality images could save about $1.32 billion over the next 10 years, according to the Society of Nuclear Medicine.
Read the original post:
Technologist Education Requirements Can Help Cut Repeat Scans
Public release date: 24-Apr-2012 [ | E-mail | Share ]
Contact: Dr Boris Kovacic Boris.Kovacic@vetmeduni.ac.at 43-125-077-5622 University of Veterinary Medicine -- Vienna
Although people generally talk about "cancer", it is clear that the disease occurs in a bewildering variety of forms. Even single groups of cancers, such as those of the white blood cells, may show widely differing properties. How do the various cancers arise and what factors determine their progression? Clues to these two issues, at least for leukaemias, have now been provided by Boris Kovacic and colleagues at the University of Veterinary Medicine, Vienna (Vetmeduni Vienna). The results are published in the current issue of the journal EMBO Molecular Medicine and have extremely important consequences for the treatment of a particularly aggressive type of leukaemia.
It is well known that many types of cancer arise as a result of a mutation within a cell and prevailing wisdom has held that the stage of differentiation of this cell determines exactly what form of cancer develops. For example, it was believed that so-called chronic myeloid leukaemia or CML arises from bone marrow stem cells, while a different type of leukaemia, known as B-cell acute lymphoid leukaemia or B-ALL, results from B-cell precursors. This belief has been spectacularly refuted by the latest results from Boris Kovacic and colleagues in the Vetmeduni Vienna's institutes of Animal Breeding and Genetics and of Pharmacology and Toxicology.
The researchers have now shown that both CML and B-ALL arise from the most primordial kind of blood cell (long-term haematopoietic stem cells), although the pathways by which the diseases progress are different. The usual causes of CML and B-ALL are two highly related versions of the same oncogene, BCR/ABL. If the primordial blood cells are transformed or made potentially cancerous by a particular version of BCR/ABL, for technical reasons termed BCR/ABLp210, the result is chronic myeloid leukaemia or CML. The long-term haematopoietic stem cells remain and act as the dreaded cancer stem cells, or CSCs, which ensure that the disease persists. Curing chronic myeloid leukaemia requires the complete elimination of the CSCs. However, if the long-term haematopoietic stem cells are transformed by a related version of BCR/ABL, BCR/ABLp185, the result is a highly aggressive form of leukaemia, B-ALL. The finding that B-ALL actually originates from the same stem cells as CML was both unexpected and highly provocative.
Kovacic and colleagues have shown further that B-ALL only develops if the transformed stem cell is exposed to a particular growth factor, interleukin-7. If interleukin-7 is present (it usually is), the transformed long-term haematopoietic stem cells undergo a differentiation step to CSCs, which in this case correspond to pro-B cells. If interleukin-7 is absent during the initial phase of transformation, B-ALL cannot develop.
In other words, two distinct types of cell are involved in leukaemia development, the primordial cells (also termed the cells of origin of cancer) and the cancer stem cells that cause the disease to progress. Unless the CSCs are eliminated, fresh cancer cells can arise at any time and the leukaemia will recur. The problem is that current leukaemia therapies are not designed to target CSCs. The primordial CSCs in CML are highly quiescent and thus difficult to target. In contrast, the CSCs in B-ALL are abundant and have a high turnover rate, which makes them susceptible to treatment. Treatment of B-ALL may thus succeed in eliminating most CSCs but if even a single cell remains intact it is likely that the patient will relapse, possibly with an even more aggressive form of leukaemia. "A therapy that targets the bulk of tumour cells will not work," as Kovacic succinctly summarizes his results. "To treat B-ALL successfully it will be necessary for us to learn much more about the development of the disease. A combined therapy is required, so future work should aim at developing drugs that target the long-term haematopoietic stem cells from which B-ALL is derived."
###
The paper "Diverging fates of cells of origin in acute and chronic leukemia" by Boris Kovacic, Andrea Hoelbl, Gabriele Litos, Memetcan Alacakaptan, Christian Schuster, Katrin M. Fischhuber, Marc A. Kerenyi, Gabriele Stengl, Richard Moriggl, Veronika Sexl and the late Hartmut Beug is published in the current issue of the journal "EMBO Molecular Medicine" (2012, Vol. 4 pp. 283-297).
The work was initiated at the Research Institute of Molecular Pathology (IMP) and was performed together with groups at the Medical University of Vienna and the Ludwig Boltzmann Institute for Cancer Research in Vienna.
Read more here:
BOLOGNA, Italy--(BUSINESS WIRE)--
Silicon Biosystems, S.p.A., a provider of specialized molecular and cellular biology technologies, will present at the Fourth World Circulating Tumour Cells Summit, April 25, 2012 at 3:30 p.m. at the Maritim Hotel in Berlin. Dr. Nicol Manaresi, founder and chief technology officer of Silicon Biosystems, will provide an overview of the DEPArray system, which uses image-based single-cell sorting to deliver pure populations of rare tumor cells.
As part of the presentation, Dr. Manaresi will also offer recent data demonstrating single-CTC molecular characterization based on Whole Genome Amplification using the companys proprietary Ampli1 WGA kit followed by sequencing with Ion Torrent.
Silicon Biosystems is a device manufacturer leading the field in the detection and isolation of single cells for cancer research and prenatal genetic testing. The companys DEPArray technology exploits microelectronics and the principles of dielectrophoresis to find, sort, isolate, and collect 100 percent pure populations of rare cells, such as CTCs, for single-cell based genomic and transcriptional profiling.
The collection of pure individual CTCs from biological samples is a game changer in the quest to obtain clinical utility of these cells as it enables individual cell-based molecular profiling for personalized therapy, going beyond existing cell counting approaches for prognostic purposes, said Manaresi. We show that 100 percent pure single-CTC sorting by DEPArray and DNA amplification with our Ampli1 WGA seamlessly integrates with Ion Torrent AmpliSeq Cancer Panel sequencing to deliver a comprehensive overview of the mutational status, cell-by-cell, in a streamlined and automated manner. To the best of our knowledge, it is the first time this has been achieved.
There are multiple large and expanding market opportunities for technology that find and isolate rare cells for molecular analysis. Silicon Biosystems DEPArray is used for translational medicine applications in metastatic cancer, cardiovascular disease, prenatal genetics, and stem cells research.
The World CTC Summit attracts important members across the CTC study community including diagnosticians, drug developers, technology providers and clinicians, said Manaresi. Silicon Biosystems is eager to join our peers and share the excitement of this achievement, and the impact of our unique method for CTC collection and analysis for the advancement of patient diagnosis and decision making.
About Silicon Biosystems
Silicon Biosystems, Inc. was formed in October 2010 as a wholly owned subsidiary of Silicon Biosystems, S.p.A. based in Bologna, Italy. The company manufactures and sells the DEPArray platform which is based on the principle of dielectrophoresis to isolate and manipulate cells in suspension with a microelectronic array. The approach, patented by Silicon Biosystems, offers the unique ability to control individual cells and micro-particles inside a disposable cartridge. The DEPArray platform makes it possible to find, sort, select and separate individual cells for further analysis or culturing. For more information on Silicon Biosystems visit http://www.siliconbiosystems.com.
More here:
23-04-2012 14:12 Today I decided to upload another collaboration with bking990, it might take a while until my next video because I have ran out of songs to upload. One song is under work but it's nowhere near finished. Thanks to bking990 again for performing such epic vocals to my songs. 😀 MP3 download: Every person on this world deserves to be free And be whatever he wants it to be Away from this darkness that'll never consume us utterly We faded away... All the passion's gone! Oh! Pray to see colored sky! This feeling will never die! Look the patriots -- thrown! Of they're mind and reason -- why they don't see the treason? I have searched and lost my mind! There is no pure soul to find! Whole this world is gone blind! Descent look will close your eyes They say that hope never dies Than what is tearing these lives? Why's darkness covered in cries? No! I cannot take you...No! I will not blame you! This burden's for me to carry! Just read obituary! All the passion's gone! Oh! Pray to see colored sky! This feeling will never die! Look the patriots -- thrown! Of they're mind and reason -- why they don't see the treason? I have searched and lost my mind! There is no pure soul to find! Whole this world is gone blind! Descent look will close your eyes They say that hope never dies Than what is tearing these lives? Why's darkness covered in cries? No! I cannot take you...No! I will not blame you! This burden's for me to carry! Just read obituary! "Breathing, walking, tearing each day ...
Read the rest here:
Obscuria - original metal song with vocals ft. bking990 - Video
24-04-2012 03:29 Haven't played acoustic in a while. Pouring my heart and soul and shit in this improvised song. Will be uploading more soon with the louder faster funner stuff. We have been recording though. Stay tuned my thousand hundred million and 2 fans. Oh and let me know what you thing so I can brag to my friends. I mean.. if you want. Stupid idea anyways to ask.
More here:
24-04-2012 10:03 Lyrics To Poison In Your Mind By Powderfinger I've tried to fix the sync with this, which is fine on my laptop but when I upload to youtube it messes it up, so I've left it at this.
Go here to see the original:
24-04-2012 11:51 Cry by Jay Sean with Lyrics on Screen and in Description. Follow Jay Sean on facebook on his homepage on Twitter Lyrics Verse1 Had me convinced that I just wasn't enough, me and you fussing and fighting cussin all of that stuff now I know, that I might 've done you wrong, didn't know I'd pay so long, til u did the same I know I'd done you wrong I was making it up to you, I apologised in a million ways but I thought that was that, but I guess you got me back, didn't know it be like that, but u did the same Bridge Now we're caught in a circle A constant battle The day that you hurt me The clouds cast a shadow on us And I hope that ur happy we're even now, so cry baby cry Chorus Let me see you cry cry cry I need to see you cry cry cry Until your tears run dry dry dry Like the deserts need the rain Want ya tears to fall down on me (x2) Before the love just turns to hate Before I ask for you to stay And just before you walk away Verse2 What is this, what happens to relationships, started off so good and ended up so bad baby I just wanna know, Ooh Tell me do u know, baby Before we knew it we were at it again, no no no, somehow I dont think we can ever be friends, wish it wasn't so, wish it wasn't so, but you did the same... Bridge (Repeat) Chorus (Repeat) Middle 8 So we go on and on on this merry go round trying to chase a love that can never be found time to say goodbye and step off of it now, its over girl its over (x2) Let ...
Read the original post:
24-04-2012 21:30 Here's a poem/spoken word piece that's pretty subpar. I think this is my second upload today. At this point in VEDA I just don't know what day is what. Help. KICKSTARTER: MAIL ME THINGS: Jake Mulford PO BOX 583572 Minneapolis, MN 55458-3572 Me, elsewhere: http Musical Endeavors:
See original here:
24-04-2012 23:13 Hay Guys Back with another upload as I try to upload every 3-4 days :), Anyways this is something that I use to do in the past just trying to get my skills back, Takes way more skill adjusting to my tablet and this program. It was a pretty good turn out so I decided to upload it. Hope You guys enjoy!. If I get 120 "LIKES" ill start doing uploading these more often! ThankYou! Final Image - Songs Logic - Mind Of Logic Ft. Camille Michelle Gray Drake - The Zone Follow me on Twitter (Very Active) - Hope you Guys Enjoy! Thanks For watching!
See more here:
(file / credit: Michael Nagle/Getty Images)
NEW YORK (CBSNewYork) The city is apparently working on a catch a creep app to help women combat forceful flirtation and other forms of street harassment.
Council Speaker Christine Quinn and Council Member Julissa Ferreras have reportedly set aside $20,000 to develop technology which would allow women to report catcalling cases and upload pictures from their smartphones of men engaged in the act.
WCBS 880s Rich Lamb On The Story
According to the Centers for Disease Control and Prevention, street harassment is the most prevalent form of sexual violence that happens to both men and women in the United States. And what we see here in New York is that it happens to girls as young as 5, 6, 7 years old, reported CBS 2s John Schriffen.
The nonprofit, Hollaback!, has apparently been enlisted to assist in producing the app. The company already has an iPhone and Android app in place designed to let women share their stories of unwanted advances. Heres how it works: You either make a complaint in writing to the organization or you can Holla right back at the catcaller by taking the persons picture.
It would teach guys if you catcall to me yo face will be on a database, student Amina Hoque told CBS 2s Schriffen.
Youre just going around taking pictures of people. I think thats kind of invasion of privacy I feel, student Luigi Clemente protested.
Speaker Quinn said the final version of the app hasnt been created yet but hopes the results will show where most of the cat calls are happening.
A construction worker told 1010 WINS John Montone that he lets women know he likes what he sees but never crosses the line.
More here:
New York City Looks To Battle Catcalling With Smartphone App
Check out some pictures that our viewers sent in today.
If you want one of your pictures to be appear on our website for our daily slideshow, send them to news@wtrf.com or brovnanik@wtrf.com. You can also upload them trough our WTRF Mobile App.
Keep in mind, once a photo is submitted, WTRF.com has the right to publish/modify/broadcast your image.
The "Pictures Around the Ohio Valley Slideshow" is only posted Monday through Friday.
See more here:
WTRF.com SLIDESHOW: Pictures Around the Ohio Valley from April 23